Selected research
Industry Research
Leucovorin Calcium Injection Industry Research Report 2026
Market perspective
The global Leucovorin Calcium Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Leucovorin Calcium Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Leucovorin Calcium Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Leucovorin Calcium Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Leucovorin Calcium Injection include BluePoint Laboratories, Get Well Pharmaceutical, Hikma, RMPL Pharma, Sagent, Fresenius Kabi, Mylan and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Leucovorin Calcium Injection market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Leucovorin Calcium Injection Market by Company
BluePoint Laboratories
Get Well Pharmaceutical
Hikma
RMPL Pharma
Sagent
Fresenius Kabi
Mylan
Teva
Leucovorin Calcium Injection Segment by Type
50mg/vial
100mg/vial
200mg/vial
350mg/vial
Leucovorin Calcium Injection Segment by Application
Hospital
Clinics
Recovery Center
Leucovorin Calcium Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leucovorin Calcium Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Leucovorin Calcium Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leucovorin Calcium Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Leucovorin Calcium Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Leucovorin Calcium Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Leucovorin Calcium Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg/vial
- 100mg/vial
- 200mg/vial
- 350mg/vial
Applications
- Hospital
- Clinics
- Recovery Center
Companies covered
- BluePoint Laboratories
- Get Well Pharmaceutical
- Hikma
- RMPL Pharma
- Sagent
- Fresenius Kabi
- Mylan
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Leucovorin Calcium Injection Market Size (2021-2032)
- 2.2.2 Global Leucovorin Calcium Injection Sales (2021-2032)
- 2.2.3 Global Leucovorin Calcium Injection Market Average Price (2021-2032)
- 2.3 Leucovorin Calcium Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 50mg/vial
- 2.3.3 100mg/vial
- 2.3.4 200mg/vial
- 2.3.5 350mg/vial
- 2.4 Leucovorin Calcium Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinics
- 2.4.4 Recovery Center
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Leucovorin Calcium Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Leucovorin Calcium Injection Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Leucovorin Calcium Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Leucovorin Calcium Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Leucovorin Calcium Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Leucovorin Calcium Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Leucovorin Calcium Injection, Product Type & Application
- 3.8 Global Manufacturers of Leucovorin Calcium Injection, Established Date
- 3.9 Global Leucovorin Calcium Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 BluePoint Laboratories
- 4.1.1 BluePoint Laboratories Company Information
- 4.1.2 BluePoint Laboratories Business Overview
- 4.1.3 BluePoint Laboratories Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 BluePoint Laboratories Leucovorin Calcium Injection Product Portfolio
- 4.1.5 BluePoint Laboratories Recent Developments
- 4.2 Get Well Pharmaceutical
- 4.2.1 Get Well Pharmaceutical Company Information
- 4.2.2 Get Well Pharmaceutical Business Overview
- 4.2.3 Get Well Pharmaceutical Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Get Well Pharmaceutical Leucovorin Calcium Injection Product Portfolio
- 4.2.5 Get Well Pharmaceutical Recent Developments
- 4.3 Hikma
- 4.3.1 Hikma Company Information
- 4.3.2 Hikma Business Overview
- 4.3.3 Hikma Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hikma Leucovorin Calcium Injection Product Portfolio
- 4.3.5 Hikma Recent Developments
- 4.4 RMPL Pharma
- 4.4.1 RMPL Pharma Company Information
- 4.4.2 RMPL Pharma Business Overview
- 4.4.3 RMPL Pharma Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 RMPL Pharma Leucovorin Calcium Injection Product Portfolio
- 4.4.5 RMPL Pharma Recent Developments
- 4.5 Sagent
- 4.5.1 Sagent Company Information
- 4.5.2 Sagent Business Overview
- 4.5.3 Sagent Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sagent Leucovorin Calcium Injection Product Portfolio
- 4.5.5 Sagent Recent Developments
- 4.6 Fresenius Kabi
- 4.6.1 Fresenius Kabi Company Information
- 4.6.2 Fresenius Kabi Business Overview
- 4.6.3 Fresenius Kabi Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Fresenius Kabi Leucovorin Calcium Injection Product Portfolio
- 4.6.5 Fresenius Kabi Recent Developments
- 4.7 Mylan
- 4.7.1 Mylan Company Information
- 4.7.2 Mylan Business Overview
- 4.7.3 Mylan Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mylan Leucovorin Calcium Injection Product Portfolio
- 4.7.5 Mylan Recent Developments
- 4.8 Teva
- 4.8.1 Teva Company Information
- 4.8.2 Teva Business Overview
- 4.8.3 Teva Leucovorin Calcium Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Leucovorin Calcium Injection Product Portfolio
- 4.8.5 Teva Recent Developments
5 Global Leucovorin Calcium Injection Market Scenario by Region
- 5.1 Global Leucovorin Calcium Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Leucovorin Calcium Injection Sales by Region: 2021-2032
- 5.2.1 Global Leucovorin Calcium Injection Sales by Region: 2021-2026
- 5.2.2 Global Leucovorin Calcium Injection Sales by Region: 2027-2032
- 5.3 Global Leucovorin Calcium Injection Revenue by Region: 2021-2032
- 5.3.1 Global Leucovorin Calcium Injection Revenue by Region: 2021-2026
- 5.3.2 Global Leucovorin Calcium Injection Revenue by Region: 2027-2032
- 5.4 North America Leucovorin Calcium Injection Market Facts & Figures by Country
- 5.4.1 North America Leucovorin Calcium Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Leucovorin Calcium Injection Sales by Country (2021-2032)
- 5.4.3 North America Leucovorin Calcium Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Leucovorin Calcium Injection Market Facts & Figures by Country
- 5.5.1 Europe Leucovorin Calcium Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Leucovorin Calcium Injection Sales by Country (2021-2032)
- 5.5.3 Europe Leucovorin Calcium Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Leucovorin Calcium Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Leucovorin Calcium Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Leucovorin Calcium Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Leucovorin Calcium Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Leucovorin Calcium Injection Market Facts & Figures by Country
- 5.7.1 South America Leucovorin Calcium Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Leucovorin Calcium Injection Sales by Country (2021-2032)
- 5.7.3 South America Leucovorin Calcium Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Leucovorin Calcium Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Leucovorin Calcium Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Leucovorin Calcium Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Leucovorin Calcium Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Leucovorin Calcium Injection Sales by Type (2021-2032)
- 6.1.1 Global Leucovorin Calcium Injection Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Leucovorin Calcium Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Leucovorin Calcium Injection Revenue by Type (2021-2032)
- 6.2.1 Global Leucovorin Calcium Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Leucovorin Calcium Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Leucovorin Calcium Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Leucovorin Calcium Injection Sales by Application (2021-2032)
- 7.1.1 Global Leucovorin Calcium Injection Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Leucovorin Calcium Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Leucovorin Calcium Injection Revenue by Application (2021-2032)
- 7.2.1 Global Leucovorin Calcium Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Leucovorin Calcium Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Leucovorin Calcium Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Leucovorin Calcium Injection Value Chain Analysis
- 8.1.1 Leucovorin Calcium Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Leucovorin Calcium Injection Production Mode & Process
- 8.2 Leucovorin Calcium Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Leucovorin Calcium Injection Distributors
- 8.2.3 Leucovorin Calcium Injection Customers
9 Global Leucovorin Calcium Injection Analyzing Market Dynamics
- 9.1 Leucovorin Calcium Injection Industry Trends
- 9.2 Leucovorin Calcium Injection Industry Drivers
- 9.3 Leucovorin Calcium Injection Industry Opportunities and Challenges
- 9.4 Leucovorin Calcium Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst